UBR5's role in aggressive breast cancer and immune evasion
UBR5's mechanisms of action in tumorigenesis and immunoregulation
Researchers are looking at how a protein called UBR5 helps aggressive breast cancers grow and hide from the immune system to find new treatment targets for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11284035 on NIH RePORTER |
What this research studies
From a patient perspective, the team is tracking how UBR5 changes cancer cell behavior and how tumors interact with the immune system. They will use lab-grown cancer cells, animal models, and analyses of human tumor samples to see how UBR5 controls proteins like CDC73 and increases immune-suppressing signals such as PDL1. The work aims to map the pathways UBR5 controls so researchers can spot potential drug targets, especially for hard-to-treat triple-negative breast cancer. Clinical data linking UBR5 alterations to worse outcomes will be combined with these lab findings to guide translational directions.
Who could benefit from this research
Good fit: Patients with aggressive breast cancer—particularly triple-negative tumors or tumors shown to have UBR5 amplification or overexpression—would be the most relevant candidates to contribute samples or be considered for future trials.
Not a fit: People with cancers that do not show UBR5 changes or those seeking immediate therapeutic benefit are unlikely to gain direct clinical benefit from this basic/translational research now.
Why it matters
Potential benefit: If successful, this work could point to new targets or strategies that lead to therapies for aggressive or treatment-resistant breast cancers.
How similar studies have performed: Prior laboratory and animal studies by this group and others have shown UBR5 can drive tumor growth, but translating UBR5-targeting approaches into patient therapies remains largely untested.
Where this research is happening
New York, United States
- Weill Medical Coll of Cornell Univ — New York, United States (Active)
Researchers
- Principal investigator: Ma, Xiaojing — Weill Medical Coll of Cornell Univ
- Study coordinator: Ma, Xiaojing
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.